ArticleScience advances2018
Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9.
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 60 citations in OpenAlex.
- From hijackers to architects: the role of prophages in bacterial genome evolution.Journal of bacteriology · 2026Review
- Rapid CRISPR-Cas9 target-strand nicking can provide phage resistance by reducing DNA abundance.Nucleic acids research · 2025Article
- Factors Affecting Phage-Bacteria Coevolution Dynamics.Viruses · 2025Review
- Harnessing bacterial immunity: CRISPR-Cas system as a versatile tool in combating pathogens and revolutionizing medicine.Frontiers in cellular and infection microbiology · 2025Review
- The role of TIR domain-containing proteins in bacterial defense against phages.Nature communications · 2024Article
- Review
- Bacteriophages: a double-edged sword in the gastrointestinal tract.Frontiers in microbiomes · 2024Review
- Landscape of New Nuclease-Containing Antiphage Systems in Escherichia coli and the Counterdefense Roles of Bacteriophage T4 Genome Modifications.Journal of virology · 2023Article
- Design of bacteriophage T4-based artificial viral vectors for human genome remodeling.Nature communications · 2023Article
- CRISPR-Cas effector specificity and cleavage site determine phage escape outcomes.PLoS biology · 2023Article
- Genome-scale top-down strategy to generate viable genome-reduced phages.Nucleic acids research · 2022Article
- Enterococcal biofilm-A nidus for antibiotic resistance transfer?Journal of applied microbiology · 2022Review
- Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing.Nucleic acids research · 2022Article
- The structure of AcrIE4-F7 reveals a common strategy for dual CRISPR inhibition by targeting PAM recognition sites.Nucleic acids research · 2022Article
- Mechanisms and clinical importance of bacteriophage resistance.FEMS microbiology reviews · 2022Review
- Novel Bacteriophages Show Activity against Selected Australian Clinical Strains ofMicroorganisms · 2022Article
- Digging into the lesser-known aspects of CRISPR biology.International microbiology : the official journal of the Spanish Society for Microbiology · 2021Review
- Engineering T4 Bacteriophage forACS synthetic biology · 2021Article
- Viral recombination systems limit CRISPR-Cas targeting through the generation of escape mutations.Cell host & microbe · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Bacteria and bacteriophages arm themselves with various defensive and counterdefensive mechanisms to protect their own genome and degrade the other's. CRISPR (clustered regularly interspaced short palindromic repeat)-Cas (CRISPR-associated) is an adaptive bacterial defense mechanism that recognizes short stretches of invading phage genome and destroys it by nuclease attack. Unexpectedly, we discovered that the CRISPR-Cas system might also accelerate phage evolution. When
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.